Evidence map›Paper›PMID 40565241›Full record

ArticleInternational journal of molecular sciences2025

Resveratrol Mitigates Inflammation by Modulating Tumor Necrosis Factor-Alpha Receptors (TNFRs) in a 2,4,6-Trinitrobenzene Sulfonic Acid (TNBS)-Induced Rat Model of Colitis.

Médea Veszelka, József Hegyközi, Nikoletta Almási, Szilvia Török, Bence Pál Barta, Izabella Nagy, Denise Börzsei, Nikolett Bódi, Mária Bagyánszki, Renáta Szabó and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Médea VeszelkaDepartment of Physiology, Anatomy, and Neuroscience, Faculty of Science and Informatics, University of Szeged, 6726 Szeged, Hungary.
József HegyköziHR-Pharma Ltd., 6726 Szeged, Hungary.
Nikoletta AlmásiDepartment of Physiology, Anatomy, and Neuroscience, Faculty of Science and Informatics, University of Szeged, 6726 Szeged, Hungary.
Szilvia TörökDepartment of Physiology, Anatomy, and Neuroscience, Faculty of Science and Informatics, University of Szeged, 6726 Szeged, Hungary.
Bence Pál BartaDepartment of Physiology, Anatomy, and Neuroscience, Faculty of Science and Informatics, University of Szeged, 6726 Szeged, Hungary.ORCID 0000-0002-5309-8633
Izabella NagyDepartment of Physiology, Anatomy, and Neuroscience, Faculty of Science and Informatics, University of Szeged, 6726 Szeged, Hungary.
Denise BörzseiDepartment of Physiology, Anatomy, and Neuroscience, Faculty of Science and Informatics, University of Szeged, 6726 Szeged, Hungary.
Nikolett BódiDepartment of Physiology, Anatomy, and Neuroscience, Faculty of Science and Informatics, University of Szeged, 6726 Szeged, Hungary.
Mária BagyánszkiDepartment of Physiology, Anatomy, and Neuroscience, Faculty of Science and Informatics, University of Szeged, 6726 Szeged, Hungary.ORCID 0000-0003-3533-9461
Renáta SzabóDepartment of Physiology, Anatomy, and Neuroscience, Faculty of Science and Informatics, University of Szeged, 6726 Szeged, Hungary.
Csaba VargaDepartment of Physiology, Anatomy, and Neuroscience, Faculty of Science and Informatics, University of Szeged, 6726 Szeged, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several substances with antioxidant and anti-inflammatory properties are currently being investigated as potential adjunctive or standalone treatments for inflammatory bowel disease (IBD). One such substance is resveratrol (RES), also known as 3,5,4'-trihydroxy-trans-stilbene, a natural dietary polyphenol with diverse health-promoting effects. In this study, male Wistar-Hannover rats received oral RES supplementation at doses of 5, 10, or 20 mg/kg/day for 28 days. On day 25 colitis was induced using intracolonic administration of 2,4,6-trinitrobenzene sulphonic acid (TNBS). Based on histological and planimetric analysis, the 10 mg/kg dose significantly reduced colonic ulceration and pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α) expression compared to the TNBS group. Immunohistochemistry also revealed that RES at this dose attenuated the intensity of TNF-α receptors, namely TNFR1 and TNFR2. Furthermore, the concentration of lipocalin-2 (Lcn-2) was significantly elevated in TNBS-induced colitis. In conclusion, our findings suggest that RES may exert its protective effects partly through the modulation of TNF receptor signaling in TNBS-induced colitis.

Indexed as

Anti-Inflammatory AgentsColitisInflammationReceptors, Tumor Necrosis FactorResveratrolAnimalsColonDisease Models, AnimalLipocalin-2MaleRatsRats, WistarReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IITrinitrobenzenesulfonic AcidTumor Necrosis Factor-alphaAnti-Inflammatory AgentsLipocalin-2Receptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IIResveratrolTrinitrobenzenesulfonic AcidTumor Necrosis Factor-alphacolon inflammationIBDoxidative stresspro-inflammatory cytokineresveratrolTNBS-induced colitisTNF-alphaTNFR-α receptor

Identifiers

PMID40565241
PMCPMC12193490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.